Abstracts tagged "outcome measures and outcomes"

Abstract Number: 1493 • 2018 ACR/ARHP Annual Meeting
Clinical Predictor Factors Associated with Sustained Disease Activity Among Patients with Early Rheumatoid Arthritis
Gabriela Gonzalez and Juan Molina, Rheumatology, La Paz University Hospital, Madrid, Spain
Background/Purpose: in rheumatoid arthritis (RA) patients the disease outcome has an unpredictable course and may differ even with an early diagnosis and treatment. Low disease…
Abstract Number: 1231 • 2017 ACR/ARHP Annual Meeting
Scope and Consistency of Adherence Related Outcomes in Randomized Controlled Trials of Interventions for Improving Medication Adherence
Ayano Kelly^1,2,3,4, Daniel Sumpton^3,5,6, Clare O'Sullivan², Alexa Meara⁷, Robby Nieuwlaat⁸, Peter Tugwell^9,10,11, Lyn March^12,13,14, Allison Tong^3,6, Karine Toupin-April¹⁵, Francois Nantel¹⁶, B.J.F. Van den Bemt (PharmD, PhD)^17,18, Mary De Vera¹⁹, Vicki Evans²⁰, Willemina Campbell²¹, Peter Wong²², Rebecca Davey²³, Dorcas Beaton^24,25,26, Maria Suarez-Almazor^27,28,29,30, Geraldine Hassett^31,32, Helen I. Keen^33,34,35, Therese Dawson³⁶, Luke Crimston-Smith³⁷ and Kathleen Tymms³⁸, ¹Rheumatology, Canberra Rheumatology, Canberra, Australia, ²Rheumatology, The Canberra Hospital, Canberra, Australia, ³Centre for Kidney Research, The Children's Hospital at Westmead, Sydney, Australia, ⁴School of Medicine, Australian National University, Canberra, Australia, ⁵Department of Rheumatology, Concord Hospital, Sydney, Australia, ⁶Sydney School of Public Health, University of Sydney, Sydney, Australia, ⁷Internal Medicine/Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁸Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada, ⁹Center For Global Health, Institute of Population Health, Ottawa, ON, Canada, ¹⁰Institute of Population Health, Center For Global Health, University of Ottawa, Ottawa General Hospital, Ottawa, ON, Canada, ¹¹Center For Global Health, Institute of Population Hlth, Ottawa, ON, Canada, ¹²Department of Rheumatology, Northern Clinical School, Institute of Bone and Joint Research, Kolling Institute, University of Sydney & Department of Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia, ¹³Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, ¹⁴Rheumatology, University of Sydney, Insitute of Bone and Joint Research, Royal North Shore Hospital, St Leonards NSW, Australia, ¹⁵Children’s Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada, ¹⁶Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁷Pharmacy, Sint Maartenskliniek and Radboudumc, Nijmegen, Netherlands, ¹⁸Pharmacy, Sint Maartenskliniek, Nijmegen, Netherlands, ¹⁹Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada, ²⁰Clear Vision Consulting, Canberra, Australia, ²¹Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ²²Mid-North Coast Arthritis Clinic and University of New South Wales Rural Clinical School, Coffs Harbour, Australia, ²³Arthritis ACT, Canberra, Australia, ²⁴Research, Mobility Program Clinical Research Unit, Li Ka Shing Knowledge Institute, St. Michaels Hospital, Toronto, ON, Canada, ²⁵Scientist, Institute for Work & Health, Toronto, ON, Canada, ²⁶Mobility Program Clinical Research Unit, St Michael's Hospital, Toronto, ON, Canada, ²⁷GIM, AT & EC, UT MD Anderson Cancer Center, Houston, TX, ²⁸Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ²⁹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine,, The University of Texas MD Anderson Cancer Center, Houston, TX, ³⁰The University of Texas MD Anderson Cancer Center, Houston, TX, ³¹Rheumatology, Liverpool Hospital, Sydney, Australia, ³²Ingham Institute, Sydney, Australia, ³³Rheumatology, Royal Perth Hospital, Perth, Australia, ³⁴Leeds, Leeds, United Kingdom, ³⁵School of Medicine and Pharmacology, University of Western Australia, Perth, Australia, ³⁶Rheumatology, Lord Street Specialist Centre, Port Macquarie, Australia, ³⁷Australian National University, Canberra, Australia, ³⁸ANU, Canberra, Australia
Background/Purpose: Poor medication adherence attenuates optimal clinical benefits and reduces the overall effectiveness of health systems. A large number of interventions targeting medication adherence have…
Abstract Number: 337 • 2015 ACR/ARHP Annual Meeting
Construct Validity of the Doyle Index in the Outcome Domain of Joint Activity in Hand Osteoarthritis Patients
W. Damman¹, R. Liu¹, M.C. Kortekaas^1,2, F.R. Rosendaal³, D. van der Heijde⁴ and M. Kloppenburg¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Flevoziekenhuis, Almere-Stad, Netherlands, ³Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The Outcome Measures in Rheumatology (OMERACT) working group on hand osteoarthritis (OA) has endorsed a preliminary set of core domains for outcome measures in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].